This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nikonenko, B. V.
Right arrow Articles by Nacy, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nikonenko, B. V.
Right arrow Articles by Nacy, C. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2007, p. 1563-1565, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01326-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs{triangledown}

Boris V. Nikonenko,1,2* Marina Protopopova,1 Rowena Samala,1 Leo Einck,1 and Carol A. Nacy1

Sequella, Inc., Rockville, Maryland 20850,1 Central Research Institute for Tuberculosis, Moscow 107564, Russia2

Received 24 October 2006/ Returned for modification 27 November 2006/ Accepted 13 January 2007

Substitution of the new diamine antibiotic SQ109 for ethambutol in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs rifampin and isoniazid, with or without pyrazinamide: at 8 weeks, lung bacteria were 1.5 log10 lower in SQ109-containing regimens.

* Corresponding author. Mailing address: Sequella, Inc., 9610 Medical Center Drive, Suite 200, Rockville, MD 20850. Phone: (301) 762-7776. Fax: (301) 762-7778. E-mail: borisnikonenko{at}sequella.com

{triangledown} Published ahead of print on 22 January 2007.

Antimicrobial Agents and Chemotherapy, April 2007, p. 1563-1565, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01326-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Nikonenko, B. V., Reddy, V. M., Protopopova, M., Bogatcheva, E., Einck, L., Nacy, C. A. (2009). Activity of SQ641, a Capuramycin Analog, in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother. 53: 3138-3139 [Abstract] [Full Text]  
  • van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»